Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 8/20 | 0.64 |
| ▸ | EDNRB | P24530 | 2/20 | 0.55 |
| ▸ | EDNRA | P25101 | 2/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9045921 | 1.00 | AR (0.64) | AREDNRBEDNRABCL2L1MCL1 | |
| SCHEMBL9045571 | 0.86 | EDNRA (0.78) | AREDNRBEDNRABCL2L1MCL1 | |
| SCHEMBL9044594 | 0.86 | EDNRA (0.78) | AREDNRBEDNRABCL2L1MCL1 | |
| SCHEMBL9047067 | 0.85 | EDNRB (0.59) | EDNRBEDNRAPOLBMEN1KMT2A | |
| SCHEMBL9677279 | 0.85 | AR (0.55) | ARBCL2L1MCL1PGRPTGES2 | |
| SCHEMBL9046291 | 0.83 | EDNRA (0.60) | EDNRBEDNRABCL2L1MCL1MEN1 | |
| SCHEMBL9052904 | 0.82 | EDNRA (0.59) | EDNRBEDNRAMEN1KMT2ARXFP1 | |
| SCHEMBL9047975 | 0.80 | EDNRA (0.56) | EDNRBEDNRAPOLBMEN1KMT2A | |
| SCHEMBL9044255 | 0.79 | ALDH1A1 (0.56) | EDNRBEDNRAPOLBTDP1MEN1 | |
| SCHEMBL9045764 | 0.79 | EDNRB (0.59) | EDNRBEDNRAPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| US-5270313-A | Treatment of circulatory disorders | HOFFMANN-LA ROCHE INC. (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |